At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
TAK-906 Maleate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis
In Brief
A Phase 2 clinical trial evaluating TAK-906 Maleate, Metaclopramide, and 1 other intervention for Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis. Completed, enrolled 51 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionMar 2018
TodayJul 2026
First PostedAug 31, 2017
Enrollment StartSep 26, 2017
Primary CompletionMar 9, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.8 years ago
Interventions
TAK-906 Maleatedrug
TAK-906 Maleate Capsules
Metaclopramidedrug
Metaclopramide Tablets
TAK-906 Maleate Placebodrug
TAK-906 placebo-matching Capsules